Drug Profile
Acamprosate - Flexion Therapeutics
Alternative Names: FX004Latest Information Update: 04 Mar 2022
Price :
$50
*
At a glance
- Originator Unknown
- Developer Flexion Therapeutics
- Class Alkanesulfonic acids; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tinnitus
Most Recent Events
- 05 Feb 2010 Phase-II clinical trials in Tinnitus in USA (unspecified route)